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Abstract
Background: Umbilical cord blood (UCB) not only contains hematopoietic stem cells (HSCs), but also non-
hematopoietic stem cells (NHSCs) that are able to differentiate into a number of distinct cell types. Based on
studies published to date, the frequency of NHSCs in UCB is believed to be very low. However, the isolation of
these cells is primarily based on their adhesion to tissue culture plastic surfaces.
Methods and results: In the current study, we demonstrate that this approach overlooks some of the extremely
immature NHSCs because they lack the ability to adhere to plastic. Using a native extracellular matrix (ECM),
produced by bone marrow (BM) stromal cells, the majority of the UCB-NHSCs attached within 4 h. The colony-
forming unit fibroblast frequency of these cells was 1.5 × 104/108 mononuclear cells, which is at least 4000-fold
greater than previously reported for UCB-NHSCs. The phenotype of these cells was fibroblast-like and different
from those obtained by plastic adhesion; they formed embryonic body-like clusters that were OCT4-positive and
expressed other human embryonic stem cell-related markers. Importantly, when implanted subcutaneously for
8 weeks into immunocompromised mice, these ECM-adherent and expanded NHSCs generated three germ layer-
derived human tissues including muscle, fat, blood vessel, bone, gland, and nerve. Moreover, injection of these
cells into muscle damaged by cryoinjury significantly accelerated muscle regeneration.
Conclusions: These results indicate that UCB may be a virtually unlimited source of NHSCs when combined with
isolation and expansion on ECM. NHSCs may be a practical alternative to embryonic stem cells for a number of
therapeutic applications.
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Background
A practical and reliable source of pluripotent and/or
multipotent stem cells holds the key to future stem cell
therapies. Despite the great potential shown by human
embryonic stem (hES) cells and induced pluripotent
stem cells (iPSCs), there are a number of challenges that
need to be overcome before they can be widely endorsed
for use in large numbers of patients suffering from various
aged-related diseases. These challenges include ethical
concerns with regard to hES cells, potential long-term
safety of transplanted iPSCs, and the considerable level of
technical skill and cost associated with preparing both
types of cells.
Umbilical cord blood (UCB) not only contains hema-
topoietic stem cells (HSCs) but also non-hematopoietic
stem cells (NHSCs) that can differentiate into many
distinct cell types including osteoblasts, chondrocytes,
myocytes, endothelial cells, and neurons [1, 2]. Based
on these findings, UCB has been proposed as an alter-
native source of mesenchymal stem cells (MSCs) for
stem cell-based therapies [3, 4]. Compared to bone
marrow (BM), a rich source of MSCs, UCB is widely
available in abundance and can be harvested with little
harm (i.e., low morbidity/mortality) to the donor [5, 6].
However, most studies report that the frequency of
NHSCs in UCB is extremely low (~5 to 350 out of 109
mononuclear cells (MNCs)) [6–9] and, compared to
BM-derived MSCs (BM-MSCs), these cells are very diffi-
cult to grow in standard culture systems [10–12]. As a re-
sult, progress in developing UCB as a source of NHSCs
for stem cell-based therapies has been largely thwarted.
Unlike HSCs, there are no reliable cell surface markers
that specifically define MSCs or NHSCs. As a result,
these cells are routinely obtained from BM and other tis-
sues (e.g., UCB) using a standardized method based on
adhesion to tissue culture plastic (TCP) [8, 13–15].
However, there is evidence that the non-adherent cell
population contains a significant number of MSCs and
the behavior of these cells is very different from those
that adhere to TCP [16–18]. Based on these observa-
tions, we hypothesized that UCB contains an extremely
immature population of NHSCs that have been previ-
ously overlooked because they fail to attach to TCP.
Previously, we reported on the production and
characterization of a native extracellular matrix (ECM)
generated by BM stromal cells [19, 20]. This ECM, de-
posited onto TCP dishes by the cells and subsequently
decellularized, is 80–100 μm thick and displays a unique
tissue-like architecture. It consists of more than 70 dif-
ferent matrix proteins including collagens, fibronectin,
small leucine-rich proteoglycans, and several basement
membrane components [19, 20]. MSCs cultured on this
BM-derived ECM (BM-ECM) exhibit enhanced attach-
ment, proliferation, and retention of stem cell properties,
including differentiation into multiple cell lineages as
well as the capacity for skeletogenesis [19–21].
The current study tests the above hypothesis and
determines whether BM-ECM facilitates the efficient
isolation of UCB-NHSCs by enhancing attachment and
proliferation and promoting the retention of their stem
cell properties.
Methods
Isolation and culture of NHSCs from human UCB
UCB was purchased from South Texas Blood & Tissue
Center (San Antonio, TX, USA). MNCs were isolated
from UCB using Ficoll-Paque Premium density media
(GE Healthcare Bio-Sciences, Pittsburgh, PA, USA) as
described previously [14]. MNCs were suspended in
“growth media” containing alpha-minimal essential
media (α-MEM; Life Technologies, Grand Island, NY,
USA), penicillin (100 U/ml), streptomycin (100 μg/ml;
Biofluids, Rockville, MD, USA), 15% pre-selected fetal
bovine serum (FBS; Becton Dickinson, Franklin Lakes,
NJ, USA), L-glutamine (4 mM), and basic fibroblast
growth factor (bFGF; 4 ng/ml) and seeded at 106 MNCs/
cm2 onto TCP that was either uncoated or coated with
fibronectin [22] or coated with ECM made by human
BM stromal cells [19, 20]. After seeding, MNC cultures
were incubated for 72 h at 37 °C to allow for attachment
of the cells and then washed twice with phosphate-
buffered saline (PBS) to remove non-adherent cells.
After washing, growth media were added and half media
changes were performed every 3 days. The adherent cells
were cultured to 70–90% confluence in a humidified at-
mosphere at 37 °C. Adherent cells (passage (P)1) were
detached from TCP surfaces using trypsin or the ECM
surface using collagenase. An aliquot of the cells (P1)
was used to determine the phenotype of the population
using flow cytometry (see below), while the remaining
cells were either used immediately or stored in liquid
nitrogen. Over 100 UCB samples were obtained from
the tissue bank and processed for this study. A subset
of 50 of these samples was used in the current study
because they had been more completely analyzed for
cell phenotype.
Human BM cells
Freshly isolated human BM-MNCs (containing MSCs),
obtained from 20- to 30-year-old donors and purchased
from ALLCELLS (Emeryville, CA, USA), were used to
prepare BM stromal cell-derived ECM (BM-ECM) as de-
scribed previously [20]. Previously, we demonstrated that
BM-ECM is superior to uncoated TCP as a culture surface
for human BM-MSCs and promotes attachment, expan-
sion, and “stemness” of these cells [20]. For the present
study, human BM-MNCs or MSCs were cultured on this
ECM for comparison with UCB-derived cells.
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Flow cytometry
Anti-CD34, CD45, CD105, and CD146 antibodies
were purchased from R&D Systems (Minneapolis,
MN, USA). Anti-CD29 and SSEA-4 antibodies were
purchased from BD Bioscience (San Jose, CA, USA).
Single-cell suspensions (1–3 × 105) were incubated for
30 min at 4 °C in 100 μl of specific antibody (10 μg/
ml). Antibody-labeled cells were washed twice with
staining buffer (PBS containing 5% fetal calf serum
(FCS) and 0.01% sodium azide) and incubated in
20 μg/ml of FITC-conjugated goat anti-mouse IgG
for 20 min at 4 °C. Cells were then washed two times
with staining buffer and either analyzed immediately
or fixed with 1% paraformaldehyde and analyzed
within 96 h using a Becton Dickinson FACStarplus
(Franklin Lakes, NJ, USA) flow cytometer with 10,000
events collected per sample. The percentage of posi-
tive cells was determined by fluorescence-activated
cell sorting (FACS). All assays were run in parallel
using cells stained with isotype IgG as a negative
control.
Determination of cell population doubling time (PDT)
UCB-derived cells (P3–5), previously maintained on
ECM, were seeded (4 × 103 cells/cm2) onto ECM-
coated plates in growth media and cultured for up
to 9 days. At harvest, adherent cells were detached
with collagenase and the number of live cells deter-
mined in triplicate. The average number of cells for
each time point was plotted against time to generate
a growth curve. PDT was determined as described
previously [23].
Immunohistochemistry
UCB-derived cells (P2), previously maintained on ECM,
were seeded (2.5–7.5 × 104 cells/cm2) onto chamber
slides and cultured for 2 days in growth media. The cells
were fixed with 4% formaldehyde for 30 min at room
temperature, washed with PBS, and then blocked for 1 h
using 5% normal goat serum containing 0.1% bovine
serum albumin (BSA). The cells were stained by incu-
bation with primary antibodies (1:100 dilution) against
OCT4, TRA-1-60, and SSEA-4 for 30 min at 4 °C.
Non-specific isotype rabbit IgG (1:100 dilution), mouse
IgM (1:100 dilution), and mouse IgG (1:100 dilution)
were used as negative controls, respectively. After
washing with PBS, samples were incubated for 20 min
with the appropriate FITC-conjugated secondary anti-
body. Specimens were mounted in DAPI-containing
medium (Vector Laboratories, Burlingame, CA, USA)
and the cells visualized using an Olympus FV500 Fluo-
view confocal microscope equipped with image analysis
software to quantify fluorescence intensity (Olympus
America, Inc., Melville, NY, USA).
Determination of colony-forming unit fibroblast and
osteoblast numbers
To determine the number of colony-forming unit fibro-
blast (CFU-F) colonies in the initial MNC population,
freshly isolated UCB cells were seeded at low seeding
density (1 × 105 MNCs/cm2) onto ECM and uncoated or
fibronectin-coated TCP surfaces and cultured at 37 °C in
growth media. Half media changes were performed every
3 days. After 1 month, the cells were fixed and stained
with crystal violet to determine CFU-F number. To as-
sess CFU osteoblast (CFU-OB) colony formation, CFU-F
colonies were maintained for an additional 25 days in
osteoblast differentiation medium (growth media supple-
mented with 100 nM dexamethasone (Sigma), 50 μML-
ascorbate-2-phosphate (Wako Chemicals, Richmond,
VA, USA), and 10 mM glycerol 2-phosphate). CFU-OB
colonies were counted after staining with von Kossa.
Adipogenesis and myogenesis
UCB-derived cells (P1–3), previously maintained on
ECM, were seeded (4 × 103 cells/cm2) onto ECM-coated
plates in growth media and cultured to confluence. To
study adipogenesis, the media were changed at conflu-
ence to differentiation media (DMEM containing 10%
FBS, 0.5 mM IBMX, 1 μM dexamethasone, 10 μg/ml in-
sulin, 100 μM indomethacin) [24] and one-half media
changes were performed every 5 days. After 20 days in
culture, adipocytes were visualized by staining with Oil
Red O. To study myogenesis, the media were changed at
confluence to differentiation media (DMEM containing
10% FBS, 5% horse serum, 10-7 M dexamethasone,
50 μM hydrocortisone) [24] and one-half media changes
were performed every 5 days. After 25 days in culture,
myotubes were identified after staining with hematoxylin
and eosin (H&E).
Cardiomyogenesis and angiogenesis
Cardiomyogenesis was induced as described previously
[25]. Briefly, UCB-derived cells (P2) or BM-MSCs (P2),
previously maintained on ECM, were seeded (106 cells/
cm2) onto TCP and cultured for 2 days in standard
growth media, followed by an additional 2 days in media
containing 5 μM 5-azacytidine (Sigma). Subsequently,
the cells were switched to differentiation media (DMEM
containing 10% FBS, 10–4 M ascorbic acid (Sigma) and
10 ng/ml transforming growth factor (TGF)-β) and
cultured for up to 25 days with media replaced every
4 days. The expression of cardiac troponin T type 2
(TNNT2) was quantified using TaqMan polymerase
chain reaction (PCR) after culture for 25 days in either
growth or differentiation media.
To study angiogenesis, UCB-derived cells (P2), previ-
ously maintained on ECM, were seeded (3 × 103 cells/cm2)
onto six-well TCP plates coated with Matrigel™ (BD
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Bioscience, San Jose, CA, USA) in 1 ml endothelial dif-
ferentiation media (EGM-2; Lonza, Switzerland) and
cultured for 7 days at 37 °C. Media changes were per-
formed every 3 days. Capillary formation was docu-
mented with brightfield photomicrographs. Baboon
endothelial progenitor cells (positive controls) were
kindly provided by Dr. Qiang Shi (TBRI, San Antonio).
BM-MSCs (P2) were used as negative controls.
Isolation of RNA and gene expression analyses using
real-time PCR
Total RNA was extracted from cultured cells using
Ultraspec™ RNA (Biotecx, Houston, TX, USA) [19].
RNA (2 μg) was reverse-transcribed using a High Cap-
acity cDNA Archive Kit (Applied Biosystems, Foster
City, CA, USA). The transcripts of interest, including
housekeeping genes (GAPDH or β-actin), were ampli-
fied from the cDNA by real-time PCR using TaqMan
Universal PCR Master Mix and TaqMan based primer
and probe sets (TaqMan gene Expression assays, Ap-
plied Biosystems). Amplification and detection were
carried out with an ABI Prism 7500 Sequence Detec-
tion System (Applied Biosystems) and gene expression
quantified by subtracting the GAPDH threshold cycle
(Ct) value from the Ct value of the gene of interest and
expressed as 2–ΔCt. RNA isolated from hES (ESI6) was
kindly provided by Dr. Peter J. Hornsby (UTHSCSA)
and served as a positive control.
In vivo implant assay
Cells (1 × 106) were loaded onto Gelfoam (Pharmacia &
Upjohn Company, MI, USA) or hydroxyapatite/trical-
cium phosphate (HA/TCP) particles (Zimmer Inc,
Warsaw, IN, USA) and implanted subcutaneously into
the dorsal surface of 10-week-old immunodeficient beige
mice (NIH-bg-nu-xid; Harlan Sprague Dawley, Indian-
apolis, IN, USA) [19] according to an approved IACUC
protocol at UTHSCSA. After 8 weeks, implants were
harvested, fixed, decalcified (HA/TCP implants only),
and embedded in paraffin. Sequential sections were
processed and stained with H&E. Bielschowsky’s silver
stain was used to identify nerve [26]. To determine the
origin of neotissues formed during implantation, a sec-
tion adjacent to the H&E stained section was stained
with an antibody specific for human nuclear ribonucleo-
protein (Millipore, Billerica, MA, USA) [27].
Green fluorescent protein labeling
To prepare ECM-adherent UCB cells stably expressing
green fluorescent protein (GFP), commercially available
Lentiviral particles (GeneCopoeia Lentifect™, LP-EGFP-
LV105-0200) were used as described in the manufac-
turer’s instructions. Cells, labeled with an efficiency
of >70%, were sorted using flow cytometry and GFP(+)
cells (95% positive) were expanded for the experiments.
Muscle regeneration using a cryoinjury animal model
A model of muscle cryoinjury was established in homozy-
gous immunodeficient RAG2–/–, γc–/– mice (Taconic,
Germantown, NY, USA) that were maintained as a breed-
ing colony and housed in a temperature-controlled, air-
filtered room with a 12-h light-dark cycle. All procedures
were performed according to an approved IACUC proto-
col at UTHSCSA.
Adult mice (8 to 12 weeks old) were anesthetized and
the gluteus maximus muscle exposed bilaterally. The
oval shaped end (4 × 6 mm) of a 12 inch long copper
probe was immersed in liquid nitrogen and then applied
to the muscle for 20 s. Following cryoinjury, 106 UCB-
NHSCs were suspended in 35 μl 50% Matrigel™ (1:1
Matrigel™ to DMEM) and 10 μl aliquots of this suspen-
sion were implanted intramuscularly in three locations
within the injured area, and then the skin was closed.
Vehicle (35 μl 50% Matrigel™) and skin fibroblasts (106
cells in 35 μl 50% Matrigel™) were used as controls. After
28 days, the animals were euthanized and muscle tissue
harvested for histology or snap frozen in liquid nitrogen
and stored at –80 °C.
Statistical analysis
To successfully predict the isolation of NHSCs from
UCB tissue, we initially employed a generalized linear
regression model using MATLAB Statistics and Ma-
chine Learning Toolbox. The independent variables
considered were: UCB sample volume, time since deliv-
ery in hours (time between tissue harvest and cell isola-
tion in the laboratory), and cell surface phenotypic
markers. The model indicated that all of the variables,
except CD146, failed to identify a combination capable
of predicting success. Next, we used a stepwise ap-
proach which excluded variables that failed to enhance
our ability to predict the successful isolation of UCB
cells. We began with the generalized linear regression
model and then, in stepwise fashion, tested whether re-
moving/adding variable(s) improved predictive power.
The final model was arrived at by reaching a point
where no single backward or forward step improved
the model’s predictive accuracy.
All data are presented as the mean ± standard deviation
(n = 3 or 6 depending on the experiment). All results were
reproduced in at least six independent experiments with
cells from six or more donors. For in vivo studies, a total
of 18 implants, using cells from six or more donors, were
performed. Statistical analyses were performed with the
Student’s t test or one-way analysis of variance (ANOVA)
with significance set at p < 0.05.
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Results
MNC phenotype varies widely with UCB donor
The expression of cell surface markers for HSCs (CD34),
MNCs (CD45), endothelial cells (CD31), and MSCs
(CD90, CD146, SSEA-4) was routinely measured upon
arrival of UCB samples at the laboratory. As experience
was gained in analyzing the samples, it became increas-
ingly clear that this initial population of MNCs was very
heterogeneous and displayed wide variation in all of the
phenotypic markers examined (e.g., CD45: range 0–96%,
median 45%; CD34: range 0–20%, median 2.2%) (Fig. 1a
and b). Subsequently, after completing the analysis of all
the samples (n = 50), it was observed that we had been
successful at obtaining UCB-NHSCs in 35% of the sam-
ples. This led us to critically examine the data, focusing
on those UCB samples where all markers had been mea-
sured, and look for potential attributes of the initial
MNC population that increased the likelihood of success-
fully isolating UCB-NHSCs. The results of performing a
generalized linear regression analysis indicated that only
CD146 expression was likely to have a non-zero coeffi-
cient (p < 0.02) (Fig. 1a). Subsequently, a stepwise linear
regression was performed and only CD146 expression was
found to predict the successful isolation of UCB-NHSCs.
Using the equation p = 0.06 (%CD146+) + 0.24 (p is the
probability of success), there is a 50% likelihood of obtain-
ing UCB-NHSCs, when the MNC population contains
4.33% CD146+, with 72% accuracy (Fig. 1c).
UCB-derived colony-forming cells adhere to ECM but not
TCP surfaces
To determine the effect of culture surface on retrieval of
NHSCs, freshly isolated MNCs were plated onto TCP
(with or without fibronectin) or ECM and incubated for
4–72 h. At the end of culture, media were removed and
the cells washed with PBS to remove non-adherent cells.
In Fig. 2a, it can be seen that an abundance of UCB-
derived fibroblast-like cells attached to the ECM in as
little as 4 h. With continued incubation (up to 72 h), cell
density increased. In contrast, relatively few cells at-
tached to TCP.
The frequency of NHSCs in UCB was measured using
CFU-F assays. When MNCs were seeded on ECM at low
density (105 MNCs/cm2), the frequency of NHSCs was
found to be approximately 1.5 × 104 colonies/108 MNCs.
This is at least 4000-fold greater than reported by others
Fig. 1 Recovery of NHSCs from UCB tissue varies widely from donor to donor, but CD146 expression is a valuable marker for predicting
successful isolation of UCB-NHSCs. a Results of performing a general linear regression, using the independent variables shown, to predict the
successful isolation of NHSCs from UCB. Although >50 UCB samples were evaluated, only 30 were analyzed for all of the listed independent
variables; in the case of CD31 and CD90, only 29 and 25 UCB samples, respectively, were analyzed. CD146 was the only marker in the original
MNC population capable of predicting the successful isolation of UCB-NHSCs (p < 0.02). b Cell surface phenotype (% positive cells) was highly
variable in the MNC populations. More than 50 UCB samples were collected and analyzed. UCB samples were not analyzed for all cell surface
markers, resulting in an unequal number of data points. The median is shown for each marker. c The percent of CD146-positive cells in the initial
MNC population is a valuable marker for predicting successful isolation of NHSCs from UCB. There is a 50% likelihood of obtaining NHSCs when
the initial population contains 4.33% CD146+ cells.
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(Fig. 2b) [6–9]. In addition, cells cultured on ECM gener-
ated embryonic body (EB)-like clusters that exhibited
OCT4-positive staining, a unique feature of ES cells (Fig.
2c and d). None of these findings were observed on TCP.
To determine if NHSCs were present in the TCP-non-
adherent population, we collected non-adherent cells
from both surfaces and reseeded them onto ECM (Fig. 3).
After 24 h, more of the TCP non-adherent cells were
found attached to the ECM than previously non-adherent
to the ECM (H&E stain) (Fig. 3a and b). Importantly, there
was a 10-fold greater number of cells attached to the
ECM, after originally being non-adherent to TCP, as com-
pared to those previously non-adherent to the ECM
(Fig. 3e). When culture on ECM was continued for CFU-F
assay, the TCP-non-adherent cells produced ~104 col-
onies/108 MNCs (Fig. 3c) while the ECM-non-adherent
Fig. 2 ECM promotes the attachment and CFU-F formation of UCB-NHSCs. a MNCs were isolated from UCB using a Ficoll-Paque Premium density
gradient, seeded (1 × 106 MNCs/cm2) onto either extracellular matrix (ECM) or uncoated tissue culture plastic (TCP), and incubated at 37 °C for up
to 72 h as described in the Methods. At harvest, non-adherent cells were removed by washing with PBS and cell attachment to the surfaces
recorded photographically under phase contrast microscopy. Scale bar = 100 μm. b Colony-forming units fibroblast (CFU-F) colony formation
by primary (P0) cultures of MNCs on ECM or TCP surfaces. CFU-Fs were fixed and stained with crystal violet. Scale bar = 100 μm. c Phase contrast
microscopy of CFU-Fs in culture. Some areas of the cultures have the appearance of embryonic bodies (EB). Scale bar = 10 μm. d OCT4, a marker
used to identify ES cells, was expressed by EB formed by the UCB-NHSCs in culture. OCT4 was detected by immunofluorescence. Non-specific
isotype IgG was used as a negative control (Neg. cont). Nuclear staining with DAPI is shown in blue. Scale bar = 10 μm
Fig. 3 Large numbers of colony-forming cells can be recovered from cultures of TCP-non-adherent UCB-NHSCs by growth on ECM. Non-adherent
(Non-ad.) UCB-NHSCs were collected from uncoated tissue culture plastic (TCP) or extracellular matrix (ECM) after 72 h of culture and then reseeded
onto ECM plates. To visualize cell attachment to the ECM (after 24 h of culture), non-adherent cells were removed by washing with PBS and the
remaining adherent cells stained with hematoxylin and eosin (H and E) (a, b). For colony-forming unit fibroblast (CFU-F) assay, the reseeded cells
were cultured for 1 month on ECM, and then fixed and stained with crystal violet (c, d). Scale bar = 100 μm. e Number of UCB-NHSCs, previously
non-adherent to uncoated TCP or ECM, collected after a second culture (rescued) on ECM for 24 h. *p < 0.05
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group produced far less (Fig. 3d). Interestingly, the num-
ber of colonies generated by TCP-non-adherent cells,
rescued on ECM, approximated that generated by cells
initially seeded on ECM (1.0 × 104 colonies/108 MNCs vs.
1.5 × 104 colonies/108 MNCs, respectively). These results
clearly suggest that UCB contains a large number of
colony-forming cells that preferentially attach to ECM.
ECM-adherent UCB-NHSCs display a pluripotent stem cell
phenotype in vitro
To determine the expansion capacity of NHSCs, cells
were seeded at the same density on the different culture
surfaces and grown for 1 month. At the end of culture,
cells on ECM were confluent, fibroblast-like, and
spindle-shaped (Fig. 4a). In contrast, cells on TCP (with
or without fibronectin) grew poorly and failed to reach
confluence. Cells that attached and grew on TCP were
round, flat, and contained an abundance of cytoplasmic
vacuoles suggestive of autophagy [28].
The phenotype of cells that grew on ECM was quite
different from those on TCP. Expression of SSEA-4, a
hES cell marker [29, 30], was found on 50% of the cells.
In addition, a number of MSC-related markers, but not
HSC markers, were expressed by 80–90% of the cells
(Fig. 4b) [15]. The cells grew vigorously through 10
passages. P5 cells, shown in Fig. 4c, have a population
doubling time of 29 h during the first 5 days in culture.
To further define the phenotype of NHSCs cultured
on ECM, we examined genes strongly expressed by hES
cells [30]. NHSCs were found to express NANOG,
OCT4, TDGF1, DNMT3B, GABRB3, Sox2, and LIN28 at
5-, 7-, 17-, 10-, 1.9-, 47- and 38-fold higher levels, re-
spectively, than BM-MSCs obtained using the same
ECM culture system (Fig. 5a). Unfortunately, it was im-
possible to obtain enough cells from TCP cultures to
conduct the experiment. To confirm the expression of
hES-associated genes by the NHSCs at the protein
level, we immunostained cells using antibodies specific
for OCT4, SSEA-4, and TRA-1-60 (Fig. 5b). In agree-
ment with the gene expression data, NHSCs strongly
expressed these ES cell-related markers as compared to
BM-MSCs (Fig. 5b). These results suggest that UCB-
NHSCs were a unique population of cells with charac-
teristics of both MSCs and ES cells.
The differentiation capacity of UCB cells (P1 to P3)
obtained by culture on ECM or TCP was examined by
reseeding onto ECM or TCP and culturing to confluence.
The cells were then switched to various differentiation
media. UCB-NHSCs grown on ECM with adipogenic
media differentiated into adipocytes (Fig. 6a). Similarly,
Fig. 4 UCB-NHSC phenotype is different when grown on uncoated TCP versus ECM. a Culture on extracellular matrix (ECM) for 1 month
promoted the growth of UCB-NHSCs better than uncoated tissue culture plastic (TCP). Phase contrast micrographs of cells cultured on the
two culture surfaces are shown at two different magnifications. b Flow cytometric analysis of UCB-NHSCs grown on uncoated TCP or ECM.
Cells grown on ECM expressed SSEA-4, an ES cell marker, as well as other MSC markers (CD29, CD105, and CD146), but not HSC markers
(CD34 and CD45). Cells stained with non-specific antibody (isotype IgG) were used as negative controls (gray peaks). The initial population of
MNCs from UCB was analyzed without culture and used for comparative purposes. c A growth curve of UCB-NHSCs maintained on ECM (P5).
Population doubling time during the first 5 days of culture was determined as described in the Methods. Cell counts are expressed as the
mean ± SD using triplicates
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cells in myogenic media differentiated and formed myo-
tubes (Fig. 6b), while cells on TCP failed to grow. To
test the cardiomyogenic potential of ECM-adherent
UCB-NHSCs, confluent cells (P2) were maintained in
differentiation media and the expression of TNNT2
[25] measured. The results showed that TNNT2 expres-
sion by the differentiated cells was increased 189-fold
compared to untreated controls (Fig. 6c). In contrast,
TNNT2 expression by BM-MSCs, similarly treated, was
only increased 28-fold with induction. Interestingly, the
basal level of TNNT2 expression by ECM-adherent
UCB-NHSCs was 19-fold higher than the BM-MSCs
and in differentiation media the difference between the
two types of cells was increased to 100-fold (Fig. 6c).
Confluent NHSCs (P2) maintained on ECM in osteo-
genic media stained strongly with von Kossa (Fig. 6d).
In contrast, no mineralization was observed with cells
on TCP. To determine the angiogenic potential of the
cells, UCB-NHSCs were seeded onto Matrigel-coated
wells and evaluated for their ability to form microvas-
culature [31]. Surprisingly, UCB-NHSCs produced a
capillary-like network within 48 h (Fig. 6e), which was
significantly faster than observed with endothelial pro-
genitors (positive controls) (data not shown).
ECM-adherent UCB-NHSCs display a pluripotent
phenotype and generate tissues in vivo
To evaluate the ability of UCB-NHSCs to generate tissue
in vivo, cells were loaded onto scaffolds and the cell-
loaded scaffolds implanted subcutaneously in immuno-
compromised mice for 8 weeks. At harvest, the implants
were processed for histology. Interestingly, implants
loaded with UCB cells, obtained from the ECM culture
system, generated multiple tissues originating from three
Fig. 5 ECM-adherent UCB-NHSCs express ES cell markers. a The gene expression profile of P2 umbilical cord blood-derived non-hematopoietic
stem cells (UCB-NHSCs) cultured on ECM was determined using TaqMan PCR. RNA isolated from human embryonic stem (ES) (ESI6) cells was used
as a positive control, while RNA harvested from human bone marrow-derived mesenchymal cells (hBM-MSCs) was used for normalization of the
data. All three types of cells were prepared, cultured on ECM, and harvested in parallel. The data shown represent the mean ± SD fold-changes
(note: log base 10 scale on y axis) in transcript level after normalization to that of BM-MSCs. b Immunofluorescent (IF) detection of OCT4, SSEA-4,
and TRA-1-60. UCB-NHSCs (P2) pre-cultured on ECM were seeded (2.5–7.5 × 104 cells/cm2) onto regular chamber slides and cultured for 2 days.
Cells were immunostained with antibodies specific for the proteins of interest. Non-specific isotype rabbit IgG, mouse IgG, and mouse IgM were
used as negative controls (Neg. cont.) for OCT4, SSEA-4, and TRA-1-60, respectively. Parallel cultures of BM-MSCs were also prepared and treated
similarly. Phase contrast micrographs of both types of cells are shown for comparative purposes. Scale bar = 10 μm
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germ layers (mesoderm: muscle, fat, blood vessel and
bone; endoderm: gland; ectoderm: nerve) (Fig. 7a). To
determine the cellular origin of the newly formed tis-
sues, histological sections adjacent to those stained with
H&E were immunostained with an antibody specific for
human nuclear ribonucleoprotein [27]. Clearly, cells
within the newly-formed tissues indicated their human
origin (Fig. 7a, except for bone). Mouse and human tissues
were used as negative and positive controls, respectively
(data not shown). Skeletal tissue, found in ossicles
within the implants, were of human origin [32]. Nerve
tissue was specifically identified using Bielschowsky’s
silver staining. In parallel, we also implanted scaffolds
with or without BM-MSCs and found no heterogeneous
tissue formation (Fig. 7b).
ECM-adherent UCB-NHSCs have the capacity to regener-
ate skeletal muscle after cryoinjury
Based on studies showing that ECM-adherent UCB-
NHSCs were able to generate muscle and blood vessels
in vitro and after in vivo implantation, we tested the
ability of these cells to regenerate skeletal muscle after
cryoinjury. In this wound model, muscle injury is
caused by touching a pre-cooled probe onto the gluteus
maximus.
For the current experiments, ECM-adherent NHSCs
were suspended in vehicle and then injected into each
of three locations in the injured muscle. Another
wound site was similarly injected with vehicle alone or
skin fibroblasts as negative controls. After 28 days, the
lesion area was measured on histological slides (Fig. 7c)
and found to be decreased in wounds treated with
NHSCs compared to vehicle- or skin fibroblast-treated
controls. Although myogenic cells infiltrated the area
around the edge of the wound, the number of myogenic
cells (91 ± 7) was significantly higher in wounds
injected with ECM-adherent cells compared to vehicle
alone (72 ± 5) (Fig. 7d). Interestingly, instead of new
muscle tissue, adipose tissue was observed in lesions
treated with vehicle or skin fibroblasts. To identify the
Fig. 6 Extracellular matrix (ECM)-adherent umbilical cord blood-derived non hematopoietic stem cells (UCB-NHSCs) display the capacity for
adipogenesis, myogenesis, osteogenesis, and angiogenesis in vitro. To examine differentiation capacity, UCB-NHSCs were seeded onto ECM or
uncoated TCP plates and cultured to confluence. At confluence, the cultures were switched to differentiation media. a UCB cells cultured on
ECM in adipocyte differentiation media formed Oil Red O-positive droplets. b UCB cells cultured on ECM in myogenic media formed myotubes
containing multi-nucleated cells on the surface of the fibers. c UCB cells, cultured on ECM in regular growth media (open bars) or cardiomyogenic
media (solid bars), expressed troponin T type 2 (TNNT2) and displayed enhanced expression in induction media. Similarly cultured human bone-
marrow-derived mesenchymal stem cells (hBM-MSCs) displayed lower levels of TNNT2 expression compared to UCB cells, but also showed increased
expression with induction media. d UCB cells, seeded at two different seeding densities (SD), were grown in osteogenic media on ECM and tissue
culture plastic (TCP) culture surfaces. Von Kossa-positive mineral deposits were only observed with culture on ECM. e UCB cells cultured on
Matrigel-coated wells developed capillary-like structures faster (48 h) than endothelial progenitor cells (positive controls, data not shown)
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Fig. 7 (See legend on next page.)
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origin of myogenic cells in the newly-formed tissue,
GFP-labeled UCB-NHSCs were injected into wound
sites. The results clearly reveal that new muscle was
produced by the implanted cells (Fig. 7e).
Discussion
In the present study, we examined more than 50 UCB
samples and achieved a 35% success rate of obtaining
NHSCs which is similar to that reported by others [33,
34]. The data support the idea that these cells originated
within the UCB and were not the result of “contamin-
ation” during collection. The relative lack of success in
retrieving NHSCs may be explained by the large pheno-
typic variation found in the UCB samples and exempli-
fied by the broad range of CD45 positive cells (0 to 96%;
median, 45%) (Fig. 1a and b). The expression of this
marker is especially informative since CD45 (“leukocyte
common antigen”) is routinely used to define popula-
tions of MNCs from peripheral blood and BM and
shows that these tissues are quite variable. To further
assess the quality and variation of the UCB samples, we
also examined the expression of CD34, a HSC marker.
In the current study, the percentage of CD34-positive
cells in the UCB MNCs was fairly low (range, 0 to 20%;
median, 2.2%), but in the range previously reported for
HSCs from peripheral blood and BM [35, 36].
Since UCB volume and “freshness” (i.e., time from
delivery/parturition to cell isolation) have been sug-
gested to predict the successful isolation of UCB cells
[34], we included these two parameters, along with cell
surface markers (Fig. 1a), in our general linear regression
analysis to determine which combination of attributes
more accurately predict success at retrieving NHSCs. It
was found that CD146 expression was the only factor
that correlated with success; the higher the percentage
of CD146 in the population, the greater the chance of
successfully isolating NHSCs. If CD146 expression
reaches 4.33%, the chance of success will be 50%. Such a
correlation may be explained by the fact that CD146 is a
marker for pericytes which have been proposed to give
rise to MSCs [37]. However, CD146-positive cells,
isolated from the initial population of MNCs by cell
sorting, failed to grow (data not shown). The fact that a
high initial seeding density is required to stimulate
NHSC growth suggests that other cells, such as MNCs,
are needed. Nevertheless, the data indicate that in future
studies it will be possible to increase our success rate by
pre-selecting UCB samples with levels of CD146 expres-
sion above the threshold derived here (e.g., 4.33%).
One of the hypotheses of the current study is that the
adhesion capacity of extremely immature NHSCs is
poor. Indeed, our data strongly demonstrate that the
majority of NHSCs fail to attach to TCP using classical
methods for obtaining stem cells. In this study, NHSCs
attached to ECM and grew rapidly for up to 10 passages,
with a cell PDT of 29 h, when both the ECM and our
modified expansion medium were provided. The NHSC
population obtained using ECM was different from that
obtained with TCP. The former consisted of a large
number of stem cells that expressed SSEA-4, a hES cell
marker, and MSC-related markers (e.g., CD29, CD105,
and CD146) that were not found in the latter. It is
widely accepted that attachment of primary NHSCs is a
critical first step that must occur before they become ac-
tivated. In our earlier studies, BM-MSCs grown on BM-
ECM demonstrated both increased cell proliferation and
retention of stem cell properties [19–21]. Here, the
ECM-based cell culture system not only enriched the
number of pluripotent stem cells obtained, but also facil-
itated the rapid expansion of these cells so that large
quantities of high-quality stem cells could be recovered.
Interestingly, our results showed that the frequency of
UCB-NHSCs was much higher than that of UCB-HSCs
(1/104–105 MNCs). Since CD146 expression was the
only factor that statistically correlated with successfully
isolating UCB-NHSCs, it is likely that UCB-NHSCs are
associated with pericytes located along the endothelial
lining of capillaries.
To definitively evaluate stem cell self-renewal and
pluripotency, in vivo studies are required. More specific-
ally, it is essential to demonstrate that the cells spontan-
eously form multiple tissues from three germ layers in
(See figure on previous page.)
Fig. 7 ECM-adherent UCB-NHSCs display a pluripotent phenotype and the capacity to regenerate skeletal muscle after cryoinjury. a ECM-adherent
NHSCs were loaded onto Gelfoam or HA/TCP particles and implanted subcutaneously into immunodeficient mice. Implants were harvested after
8 weeks, processed for histological analysis, and stained with H&E (upper panels); Bielschowsky’s silver stain was used to identify nerve (see lower panel
of “Nerve”) [26]. Sections were also immunostained for human nuclear ribonucleoprotein to confirm the origin of the cells responsible for neotissue
formation (see middle row of panels except “bone”) [27]. Skeletal tissue (Bone) is only stained with H&E. Key to labels: a, artery; b, bone; c, capillary; e,
endothelial cells; f, fat; g, gland; m, muscle; and n, nerve. b BM-MSCs were loaded onto Gelfoam carriers and implanted as controls. All procedures for
experimental and control groups were performed at the same time. H&E stained sections demonstrated that BM-MSCs did not form heterogeneous
tissues. c Histological cross sections of cryoinjured muscle tissue from immunodeficient mice treated with Matrigel alone (vehicle), Matrigel containing
skin fibroblasts, or Matrigel containing extracellular matrix (ECM)-adherent umbilical cord blood (UCB) cells for 28 days. The perimeter of the wound is
demarcated using dark blue dots. d Tissue morphology after H&E staining. UCB cells resulted in healing and a greater number of myogenic cells
around the wound. Scale bar = 100 μm. e GFP-labelled UCB cells were injected into cryoinjured muscle to confirm that the cells were of human
origin. Immunofluorescent (IF) staining demonstrated muscle regeneration by the labeled cells
Wu et al. Stem Cell Research & Therapy  (2016) 7:176 Page 11 of 14
vivo without the use of differentiation-inducing agents
[38]. Previously, “embryonic-like stem cells” from UCB
were identified based on the expression of several
markers associated with pluripotency without in vivo
validation [14, 39]. However, marker expression, either
at the mRNA or protein level, is not sufficient to dem-
onstrate true stem cell pluripotency [40]. In particular,
in vitro differentiation, induced by high concentrations
of various reagents, is subject to artifact and a high level
of false positives [41]. Our in vivo studies clearly indicate
that UCB-NHSCs, obtained using the ECM culture system
without inducing agents, were able to generate tissues
from the three germ layers. Whether these heterogeneous
tissues were generated from authentic pluripotent stem
cells or lineage-committed cells remains to be clarified.
Since the in vivo results showed that UCB-NHSCs gener-
ated enormous amounts of muscle and blood vessels, we
further evaluated the capacity of these cells to repair skel-
etal muscle using a cryoinjury model. The results, using
GFP-labeled UCB-NHSCs, showed that the majority of
the newly-formed muscle was generated by the labeled
NHSCs. In addition, the injected UCB-NHSCs may also
recruit endogenous muscle progenitor cells to participate
in tissue repair and this may explain the finding that
some newly-formed muscle was not stained with GFP.
Consistent with this idea, others have previously re-
ported that transplanted MSCs have the capacity to re-
activate endogenous stem cells in other organs [42, 43].
In our in vivo studies with NHSCs, teratoma formation
was never observed. This may be explained by the modest
expression of various ES cell-related genes, such as LIN28
which is associated with the promotion of human cancers
[44, 45]. In the present study, LIN28 expression by ECM-
adherent UCB-NHSCs was much lower than that of hES
cells, even though it was about 37-fold higher than that
of BM-MSCs. Ontologically, our findings suggest that
NHSCs, obtained using the ECM, are closer to hES cells
than BM-MSCs.
Although hES cells exhibit unlimited self-renewal and
the capacity to differentiate into tissues from all three
germ layers, the source (human embryos) of these cells
raises ethical issues that restrict them from becoming a
viable cell-based therapy. A number of the challenges
associated with hES cells may be resolved by using iPSCs
[46, 47]. However, iPSC technology is still in its infancy
and there are many technical barriers to overcome be-
fore they can be used therapeutically [48, 49]. Here we
report a new approach that enables the isolation of
natural and highly multipotent NHSCs from an unlim-
ited source, UCB, and that provides sufficient amounts
of cells for systematic characterization. Given that the
global birth rate is around 100 million per year [50],
UCB remains the largest source of stem cells available.
This virtually unlimited source of NHSCs makes them a
viable alternative to hES cells for cell-based clinical
applications. The information gained from this study
will likely motivate the development of additional in
vivo models for evaluating the use of NHSCs in various
clinical applications.
Conclusions
The results reported here support the existence of
embryonic-like stem cells or highly primitive NHSCs in
UCB [39, 51]. Importantly, the present study showed
that: 1) the frequency of UCB-NHSCs is at least 4000-fold
greater than that previously reported by others [6, 7, 9]; 2)
ECM-adherent UCB-NHSCs form embryonic bodies that
are OCT4-positive and express other hES cell-related
markers; 3) UCB-NHSCs generate multiple tissues that
originate from three embryonic germ layers in vivo; and 4)
UCB-NHSCs accelerate skeletal muscle regeneration after
cryoinjury. To the best of our knowledge, this is the first
report that describes a method for successfully isolating
substantial quantities of NHSCs from UCB and provides a
characterization of these cells.
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